First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

Betsy Goodfellow | November 9, 2023 | News story | Research and Development |  AdvanCell, Cancer, Oncology, clinical trial, prostate cancer 

AdvanCell has announced that the first patient has been dosed with ²¹²Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive metastatic Castration Resistant Prostate Cancer (mCRPC) treatment.

²¹²Pb-ADVC001 is designed to bind to PSMA, a clinically validated cell surface target that is often highly expressed in prostate cancer, with the drug having already been optimised for safety and efficacy and demonstrating potential best-in-class attributes during preclinical studies.

The phase 1/2 trial is a multi-centre, open-label study which will assess the safety and efficacy of the drug candidate in patients with PSMA-positive mCRPC, aiming to find a recommended phase 2 dose. Secondary objectives include measuring dosimetry, rPFS by RECIST and PSMA PET-CT and PSA response.

Andrew Adamovich, AdvanCell’s chief executive officer, commented: “The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the company, our scientists, clinical trial sites and our patients. We believe that ²¹²Pb is the ideal radioisotope to realise the full therapeutic power of Targeted Alpha Therapy. This promise is strongly supported by preclinical results for ²¹²Pb-ADVC001, which demonstrate the potential for best-in-class safety and efficacy.”

Betsy Goodfellow